Filing Flows › Fulgent Genetics (FLGT) › Q3 2026 › vs Q2 2026
Fulgent Genetics (FLGT) Q3 2026 vs Q2 2026 (quarter over quarter)
Fulgent Genetics's revenue rose $5.0M (+6%) from $85.4M in Q2 2026 to $90.4M in Q3 2026.
Fulgent Genetics, Q3 2026: revenue $90.4M (+8% year over year), operating margin -24.9%, net loss $13.3M, operating cash flow $109M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 118.8% | -32.3% | +151.2 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $90.4M | $85.4M | $5.0M | +6% |
| Other income, net | $8.5M | $6.4M | $2.1M | +33% |
| Income tax benefit | $704K | −$29K | $733K | — |
| Net loss | $13.3M | $29.7M | −$16.4M | -55% |
| Costs & expenses | $113M | $121M | −$8.5M | -7% |
| Operating costs | $113M | $121M | −$8.5M | -7% |
| Cost of revenue | $58.5M | $59.7M | −$1.2M | -2% |
| Research & development | $13.6M | $14.6M | −$918K | -6% |
| Sales & marketing | $15.6M | $15.2M | $378K | +2% |
| General & admin | $22.8M | $27.2M | −$4.4M | -16% |
| Other operating costs | $2.5M | $4.8M | −$2.3M | -48% |
| Operating cash sources | $123M | $6.0M | $117M | 21× |
| Depreciation & amortization | $6.8M | $7.7M | −$860K | -11% |
| Share-based compensation | $8.1M | $8.6M | −$504K | -6% |
| Working capital & other | $108M | −$10.3M | $118M | — |
| Net loss absorbed | $13.3M | $29.7M | −$16.4M | -55% |
| Operating cash flow | $109M | −$23.8M | $133M | — |
| Free cash flow (OCF − capex) | $107M | −$27.6M | $135M | — |
| Capital expenditures | $1.8M | $3.9M | −$2.1M | -54% |
Questions
How much did Fulgent Genetics's revenue grow quarter over quarter in Q3 2026?
Fulgent Genetics's revenue rose $5.0M (+6%) from $85.4M in Q2 2026 to $90.4M in Q3 2026.